The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites
Open accessAbstract
BACKGROUND: A malaria vaccine could be an important addition to current control strategies. We report the safety and vaccine efficacy (VE) of the RTS,S/AS01 vaccine during 18 mo following vaccination at 11 African sites with varying malaria transmission. METHODS AND FINDINGS: 6,537 infants aged 6-12 wk and 8,923 children aged 5-17 mo were randomized to receive three doses of RTS,S/AS01 or comparator vaccine. VE against clinical malaria in children during the 18 mo after vaccine dose 3 (per protocol) was 46% (95% CI 42% to 50%) (range 40% to 77%; VE, p<0.01 across all sites). VE during the 20 mo after vaccine dose 1 (intention to treat [ITT]) was 45% (95% CI 41% to 49%). VE against severe malaria, malaria hospitalization, and all-cause hospitalization was 34% (95% CI 15% to 48%), 41% (95% CI 30% to 50%), and 19% (95% CI 11% to 27%), respectively (ITT). VE against clinical malaria in infants was 27% (95% CI 20% to 32%, per protocol; 27% [95% CI 21% to 33%], ITT), with no significant protection against severe malaria, malaria hospitalization, or all-cause hospitalization. Post-vaccination anti-circumsporozoite antibody geometric mean titer varied from 348 to 787 EU/ml across sites in children and from 117 to 335 EU/ml in infants (per protocol). VE waned over time in both age categories (Schoenfeld residuals p<0.001). The number of clinical and severe malaria cases averted per 1,000 children vaccinated ranged across sites from 37 to 2,365 and from -1 to 49, respectively; corresponding ranges among infants were -10 to 1,402 and -13 to 37, respectively (ITT). Meningitis was reported as a serious adverse event in 16/5,949 and 1/2,974 children and in 9/4,358 and 3/2,179 infants in the RTS,S/AS01 and control groups, respectively. CONCLUSIONS: RTS,S/AS01 prevented many cases of clinical and severe malaria over the 18 mo after vaccine dose 3, with the highest impact in areas with the greatest malaria incidence. VE was higher in children than in infants, but even at modest levels of VE, the number of malaria cases averted was substantial. RTS,S/AS01 could be an important addition to current malaria control in Africa. TRIAL REGISTRATION: www.ClinicalTrials.gov NCT00866619 Please see later in the article for the Editors' Summary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424 · cited 1×
“However, in 2012 Plasmodium falciparum still caused an estimated 207 million cases of malaria and 627,000 deaths, mostly in young children in sub-Saharan Africa [3], and the gains that have been made recently in malaria control are threatened by emerging insecticide and drug resistance [4,5].”
BackgroundInsecticide-treated bed nets and curtains for preventing malaria
Lengeler, C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000363.pub2 · Cited by 1,700
Global malaria mortality between 1980 and 2010: a systematic analysis
Murray, C. J., Rosenfeld, L. C., Lim, S. S., Andrews, K. G., Foreman, K. J., Haring, D., Fullman, N., Naghavi, M., Lozano, R., & Lopez, A. D. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60034-8 · Cited by 1,452 · cited 1×
“Considerable gains have been made in the control of malaria during the past decade as a result of improved diagnosis, introduction of effective treatment with artemisinin combination therapy (ACT), and widespread deployment of insecticide-treated nets (ITNs) [1,2].”
BackgroundA new world malaria map: Plasmodium falciparum endemicity in 2010
Gething, P. W., Patil, A. P., Smith, D. L., Guerra, C. A., Elyazar, I. R., Johnston, G. L., Tatem, A. J., & Hay, S. I. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-378 · Cited by 1,146
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Bojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R., Conway, D. J., Reece, W. H., Gothard, P., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06957-4 · Cited by 528
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
Cited by
Bache, E. B., Agnandji, S. T., Lell, B., Fernandes, J. F., Abossolo, B. P., Kabwende, A. L., Adégnika, A. A., Mordmüller, B. G., Kremsner, P. G., Loembé, M. M., et al. (2015) · The Lancet · doi:10.15496/publikation-6508 · Cited by 642
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Didierlaurent, A. M., Laupèze, B., Di Pasquale, A., Hergli, N., Collignon, C., & Garçon, N. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1213632 · Cited by 516
Datoo, M. S., Natama, M. H., Somé, A., Traoré, O., Rouamba, T., Bellamy, D., Yameogo, P., Valia, D., Tegneri, M., Ouedraogo, F., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00943-0 · Cited by 452
Liver-Resident Memory CD8+ T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection
Fernandez-Ruiz, D., Ng, W. Y., Holz, L. E., Ma, J. Z., Zaid, A., Wong, Y. C., Lau, L. S., Mollard, V., Cozijnsen, A., Collins, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.011 · Cited by 438
Malaria medicines: a glass half full?
Wells, T. N. C., van Huijsduijnen, R. H., & Van Voorhis, W. C. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4573 · Cited by 430
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
Neafsey, D. E., Juraska, M., Bedford, T., Benkeser, D., Valim, C., Griggs, A., Lievens, M., Abdulla, S., Adjei, S., Agbenyega, T., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505819 · Cited by 422
Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children
Olotu, A., Fegan, G., Wambua, J., Nyangweso, G., Leach, A., Lievens, M., Kaslow, D. C., Njuguna, P., Marsh, K., & Bejon, P. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515257 · Cited by 421
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Hanson, M. C., Crespo, M. P., Abraham, W., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79915 · Cited by 381
Malaria eradication within a generation: ambitious, achievable, and necessary
Feachem, R. G. A., Chen, I., Akbari, O., Bertozzi-Villa, A., Bhatt, S., Binka, F., Boni, M. F., Buckee, C., Dieleman, J., Dondorp, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31139-0 · Cited by 366
White, M. T., Verity, R., Griffin, J. T., Asante, K. P., Owusu-Agyei, S., Greenwood, B., Drakeley, C., Gesase, S., Lusingu, J., Ansong, D., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00239-x · Cited by 354
Portugal, S., Tipton, C. M., Sohn, H., Kone, Y., Wang, J., Li, S., Skinner, J., Virtaneva, K., Sturdevant, D. E., Porcella, S. F., et al. (2015) · eLife · doi:10.7554/elife.07218 · Cited by 329
Systems analysis of protective immune responses to RTS,S malaria vaccination in humans
Kazmin, D., Nakaya, H. I., Lee, E. K., Johnson, M. J., van der Most, R., van den Berg, R. A., Ballou, W. R., Jongert, E., Wille-Reece, U., Ockenhouse, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621489114 · Cited by 293
Lynn, D. J., Benson, S. C., Lynn, M. A., & Pulendran, B. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00554-7 · Cited by 289
Malaria vaccines since 2000: progress, priorities, products
Duffy, P. E., & Patrick Gorres, J. (2020) · npj Vaccines · doi:10.1038/s41541-020-0196-3 · Cited by 266
Ismail, H. M., Barton, V., Phanchana, M., Charoensutthivarakul, S., Wong, M. H. L., Hemingway, J., Biagini, G. A., O’Neill, P. M., & Ward, S. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600459113 · Cited by 261
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C., & Hill, A. V. S. (2017) · Scientific Reports · doi:10.1038/srep46621 · Cited by 253
Suscovich, T. J., Fallon, J. K., Das, J., Demas, A. R., Crain, J., Linde, C. H., Michell, A., Natarajan, H., Arevalo, C., Broge, T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb4757 · Cited by 142
Bowman, N. M., Akialis, K., Cave, G., Barrera, R., Apperson, C. S., & Meshnick, S. R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196410 · Cited by 72
Varo, R., Chaccour, C., & Bassat, Q. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.05.024 · Cited by 31
Owalla, T. J., Hergott, D. E. B., Seilie, A. M., Staubus, W., Chavtur, C., Chang, M., Kublin, J. G., Egwang, T. G., & Murphy, S. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1003452 · Cited by 9
Metadata
- Authors
- The RTS, S. C. T. P. (.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-07-29
- Volume
- 11
- Issue
- 7
- Pages
- e1001685
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W65828984
- Cited by
- 474
- References
- 31
- FWCI
- 51.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.